Skip to Content

尊敬的客户：

目前国际形势复杂多变，关税政策尚不明朗，这可能对我们的产品价格产生一定影响。在此情况下，我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性，如果您选择在此期间下单，我们将保留根据实际情况调整价格的权利。同时，我们也理解市场变化可能给您带来的困扰，因此如果在订单实际发货前因关税政策变动导致价格出现较大波动，默克将与您进行协商讨论并视情况对订单进行调整或取消。

Merck
CN
All Photos(2)

Key Documents

View All Documentation

569223-U

Supelco

Discovery® C18 (5 µm) HPLC Columns

L × I.D. 10 cm × 4.6 mm, HPLC Column

Synonym(s):

Discovery RP18 HPLC Column

Sign Into View Organizational & Contract Pricing

Select a Size

1 EA
¥11,407.80

¥11,407.80

Please contact Customer Service for Availability
All Photos(2)

Select a Size

Change View
1 EA
¥11,407.80

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

¥11,407.80

Please contact Customer Service for Availability

Product Name

Discovery® C18 HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm

material

stainless steel column

Quality Level

100

Agency

suitable for USP L1

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

12% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
67034U67033U66825U
BIOshell A400 Protein C4, 3.4 μm HPLC Column 3.4 μm particle size, L × I.D. 15 cm × 300 μm

67039U

BIOshell A400 Protein C4, 3.4 μm HPLC Column

BIOshell A400 Protein C4, 3.4 μm HPLC Column 3.4 μm particle size, L × I.D. 15 cm × 100 μm

67034U

BIOshell A400 Protein C4, 3.4 μm HPLC Column

Supelco

67033U

BIOshell A400 Protein C4, 3.4 μm HPLC Column

BIOshell A400 Protein C4, 3.4 μm HPLC Column 3.4 μm particle size, L × I.D. 10 cm × 2.1 mm

66825U

BIOshell A400 Protein C4, 3.4 μm HPLC Column

matrix

spherical silica particle platform, superficially porous particle

matrix

spherical silica particle platform, superficially porous particle

matrix

spherical silica particle platform, superficially porous particle

matrix

spherical silica particle platform, superficially porous particle

separation technique

reversed phase

separation technique

reversed phase

separation technique

reversed phase

separation technique

reversed phase

particle size

3.4 μm

particle size

3.4 μm

particle size

3.4 μm

particle size

3.4 μm

matrix active group

C4 (butyl) phase

matrix active group

C4 (butyl) phase

matrix active group

C4 (butyl) phase

matrix active group

C4 (butyl) phase

pore size

400 Å

pore size

400 Å

pore size

400 Å

pore size

400 Å

technique(s)

HPLC: suitable, UHPLC-MS: suitable, LC/MS: suitable, UHPLC: suitable

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

General description

Use Discovery® C18 for any method that specifies a C18. The exceptional peak shape, reproducibility, and stability make it the column of choice for all C18 methods from demanding to routine.

Application


  • Development of an HPLC-based guanosine monophosphate kinase assay and application to Plasmodium vivax guanylate kinase.: Utilizes the Discovery® C18 HPLC Column for developing a novel enzymatic assay, aiding in malaria research and potential therapeutic target exploration (Pedro et al., 2019).

Features and Benefits

  • Excellent reproducibility
  • Exceptional peak shape for basic and acidic analytes
  • Stable, low-bleed LC-MS separations
  • Separation of peptides and small proteins
  • Lower hydrophobicity than many comparable C18 columns, providing faster analysis

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
283930-06
283930-05
283930-04
283930-03
283930-02

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T R Shantha Kumar et al.
Journal of pharmaceutical and biomedical analysis, 38(1), 173-179 (2005-05-24)
A simple, precise and accurate isocratic reverse-phase liquid chromatography method with programmed wavelength detection has been validated to quantify DRF-4367 and Phenol red, simultaneously for application in rat in situ single pass intestinal perfusion study to assess intestinal permeability of
Abbas Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(24), 2423-2429 (2011-07-26)
A novel isocratic reversed-phase high performance liquid-chromatography/ultraviolet detection method for simultaneous determination of cefdinir and cefixime in human plasma was developed and validated after optimization of various chromatographic conditions and other experimental parameters. Sample preparation based on a simple extraction
Himal Paudel Chhetri et al.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 22(5), 483-487 (2014-12-05)
This study presents the optimization of a simple HPLC-UV method for the determination of metformin in human plasma. Ion pair separation followed by UV detection was performed on deproteinized human plasma samples. The separation was carried out on a Discovery
Ramisetti Nageswara Rao et al.
Journal of separation science, 32(9), 1312-1322 (2009-04-29)
Modafinil, adrafinil and their related substances were synthesized and analyzed by RP-LC with ESI-MS/MS. The ionization mode, polarity, cone voltage, and chromatographic conditions were evaluated. The optimum LC-MS conditions to obtain fragment ions indispensable for identification of the structures were
Sheelendra Pratap Singh et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(27), 2845-2851 (2011-09-06)
Tamoxifen is the agent of choice for the treatment of estrogen receptor-positive breast cancer. Tamoxifen is a substrate of P-glycoprotein (P-gp) and microsomal cytochrome P450 (CYP) 3A, and biochanin A (BCA) is an inhibitor of P-gp and CYP3A. Hence, it
View All Related Papers

Related Content

Discovery C18 and C8 HPLC Columns

Discovery C18 and C8 HPLC Columns products offered

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service